



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

Meeting: Tuesday August 21, 2018 3:30pm – 5:30pm
451 Junction Road
Madison, WI
UW West Clinic Room 1287

Enter the clinic... proceed left past the vending area... turn left again and conference room 1287 is the last one on the left.

Group Information:

Jayne Schwartz 608- 244-2120
schwartzdon@sbcglobal.net

Madison Multiple Myeloma Support Group website
madisonmultiplemyeloma.org

Mailing Address: Wisconsin Multiple Myeloma Support Group
3309 Chicago Avenue Madison, WI 53714-1815

Information Sources :

International Myeloma Foundation (IMF)
Phone: 800 - 452 - 2873
Email: TheIMF@myeloma.org
Website: www.myeloma.org

Multiple Myeloma Research Foundation(MMRF)
Phone: 203 - 972 - 1250
Email: info@themmrf.org
Website: www.multiplemyeloma.org

Upcoming Meeting Speakers... **Mark your calendars now!**

Dr Sara Christensen Holz, Associate Professor Dept of Orthopedics and Rehabilitation will reschedule. More information to follow. She will talk about balance issues and neuropathy.

Nancy Bruno, IMF Regional Director of Support Groups will join us for the September meeting. She is coming from Atlanta, Georgia to meet with us and share new information.

Dr Natalie Callander will join us for our October meeting. More information to follow.

Carly Borchert, Clinical Nurse Consultant-Milwaukee District, Celgene Corporation will be our December speaker. Carly will present “The Myeloma Central Tour” and speak briefly about the Myeloma Crowd.

August meeting - Jill Helgeson, Lead Medigap Helpline Coordinator - She is one of our favorite guest speakers! She will present “Fitting The Pieces Around Medicare”. Don't miss this meeting.



“On Course for A Cure 2018”, the 2nd annual golf outing was held on August 13, 2018. The event was a huge success. It was great to see so many group members attending. This event was a fund raiser for the UW Trillium Research. To all of you that participated, whether you golfed, just dined with us or sent a donation.... Thank you everyone!

Wisconsin State Journal, August 12, 2018

Collectar Biosciences, a Madison company working on cancer-fighting medications, is cheering early patient test results of its main compound, but it has ended production of the drug here, cutting jobs, and last week the company learned its supply of the drug has been temporarily halted by federal regulators.

CLR 131, Collectar’s lead drug candidate, is being tested on patients with recurrences of a variety of blood cancers, including multiple myeloma and several types of lymphoma, in a phase 2 trial.

Initial results in patients with diffuse large B-cell lymphoma, show that after a single dose of CLR 131, 33 percent of the patients saw their tumors reduced, in amounts ranging from 60 percent to more than 90 percent. The company did not say how many people were in that group. Half of the participants had some tumor shrinkage or their conditions were stabilized after receiving the medication.

“We are very encouraged by the strong response rates and meaningful reductions in tumor volumes,” Collectar CEO James Caruso said.

In a companion report, the company said a woman with Waldenstrom macroglobulinemia, a rare form of non-Hodgkin’s lymphoma, who received one dose of CLR 131 had more than a 50 percent reduction in her tumors when she was tested 52 days later. She received a second dose 10 weeks later, and after two months, a scan showed her tumors were 94 percent smaller, with four of five tumors gone.

It was a “very dramatic response,” said Dr. Sikander Ailawadhi, the physician who treated the woman at The Mayo Clinic in Jacksonville, Florida. But, he added, it is too soon to tell how long the response will last or if there are long-term side effects.

Even though the initial results involve a small number of patients, they are noteworthy, said Collectar chief medical officer Dr. John Friend. They show potential investors and the public that CLR 131 has “a significant impact across a variety of hematological cancers,” including “hard-to-treat, highly aggressive lymphomas,” he said.

The phase 2 study is being conducted at 10 cancer centers around the U.S. and is expected to involve as many as 80 patients. If the tests continue to go well, Collectar could apply for U.S. Food and Drug Administration approval by 2022, Friend said./

A study will begin this fall on the drug’s impact on pediatric tumors, and in 2019, in a collaboration with the UW-Madison’s Carbone Cancer Center, it will be tested along with radiation for treating recurring head and neck cancer.

